ADDF Diagnostics Accelerator Funding for FTD Biomarker Development
ADDF Diagnostics Accelerator Funding for FTD Biomarker Development supports FTD researchers through a partnership with The Association for Frontotemporal Degeneration to advance biomarkers for diagnosis and treatment.
Funder: The Association for Frontotemporal Degeneration
Due Dates: Not listed for this funding partnership
Funding Amounts: Close to $5 million in total FTD biomarker funding; past awards of $250,000, $500,000, and $1,200,000
Summary: AFTD and the Alzheimer’s Drug Discovery Foundation support FTD biomarker development through the Diagnostics Accelerator.
Description
The Association for Frontotemporal Degeneration (AFTD) partners with the Alzheimer’s Drug Discovery Foundation (ADDF) to fund frontotemporal degeneration (FTD) biomarker development through ADDF’s Diagnostics Accelerator. Launched in 2018, the accelerator backs promising research that may not offer an immediate commercial return while retaining a focus on developing products for the marketplace.
The partnership directs that approach toward FTD-focused biomarker projects as part of AFTD and ADDF’s broader work to advance FTD diagnosis and treatment. Its funded portfolio includes work on fluid biomarkers of neurodegeneration, plasma TDP-43, and remote blood-biomarker monitoring.
